An Integrative Review of Chronic Fatigue Syndrome (CFS): Clinical Insights and Therapeutic Approaches in Unani and Modern Medicine
Abstract
Excruciating fatigue that lasts for at least six months is a defining feature of the complicated illness known as chronic fatigue syndrome (CFS). With a prevalence of 0.4% to 2.5% worldwide, CFS is becoming more common. CFS impacts more women than men. In wealthy nations, it is considered a common condition. Although CFS has no recognized cure, symptoms can be controlled and managed. Daily normal activities are significantly hampered by chronic fatigue. An imbalance of brain neurotransmitters, mitochondrial dysfunction, reduced oxidative phosphorylation, disruption of the hypothalamic-pituitary-adrenal (HPA) axis, and decreased ATP synthesis are all essential components of the pathophysiology of CFS. The current study aims to identify the herbs used as medicine for chronic fatigue syndrome (CFS) and to examine the current treatment strategies for it. The phytochemicals found in the Unani medicinal plants discussed in this article make them highly effective in treating the symptoms of chronic fatigue syndrome. The current treatment approach for chronic fatigue syndrome is also briefly covered in this review article. It includes cognitive-behavioral therapy (CBT), graded exercise therapy (GET), immunoglobulin use, psychodynamic counseling, and isometric exercises that are very helpful in reducing the symptoms of CFS. Conventional treatments for CFS include corticosteroids, immunomodulatory drugs, and antidepressants. Various Unani medicinal plants are examined in this article, along with their pharmacological characteristics, potential uses, and available therapies for mitigating the symptoms of chronic fatigue syndrome.
Keywords: chronic fatigue syndrome, brain neurotransmitters, mitochondrial dysfunction, reduced oxidative phosphorylation
Keywords:
chronic fatigue syndrome, brain neurotransmitters, mitochondrial dysfunction, reduced oxidative phosphorylationDOI
https://doi.org/10.22270/jddt.v15i8.7295References
1. Afari N, Buchwald D. Chronic Fatigue Syndrome: A Review. Am J Psychiatry. 2003;160(2):221-236. https://doi.org/10.1176/appi.ajp.160.2.221 PMid:12562565
2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953-959. https://doi.org/10.7326/0003-4819-121-12-199412150-00009 PMid:7978722
3. Ibn nafees B K ibn Ooz. "kulliyat-eNafeesi" Vol.2.(Urdu Translation) Hydrabad: (Deccan);1952:19, 59-74, 266- 268, 269-272, 491.
4. Zakariya Razi (1991),'Kitab-Al-Mansoori', (urdutranslation) New Delh; CCRUM; YNM: 59-80.
5. Saifi MW, Fahad A, Bihari L, Nuzhat, Nilofar S, Fatma KF, Almas U, Shams NF, Jamal Y. An Observational Analytical Study of the Fatigue Index in Young Adult with Reference to Different Mizaj. Int J Adv Health Sci. 2024;11(4):1-9.
6. Richman JA, Flaherty JA, Rospenda KM: Chronic fatigue syndrome: have flawed assumptions been derived from treatment-based studies? Am J Public Health 1994; 84:282-284 https://doi.org/10.2105/AJPH.84.2.282 PMid:8296954 PMCid:PMC1615008
7. Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D: Prevalence of the chronic fatigue syndrome in an Australian population. Med J Aust 1990; 153:522-528. https://doi.org/10.5694/j.1326-5377.1990.tb126191.x PMid:2233474
8. Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang CF, Plioplys S: A community based study of chronic fatigue syndrome. Arch Intern Med 1999; 159:2129-2137 https://doi.org/10.1001/archinte.159.18.2129 PMid:10527290
9. Steele L, Dobbins JG, Fukuda K, Reyes M, Randall B, Koppelman M, Reeves WC: The epidemiology of chronic fatigue in San Francisco. Am J Med 1998; 105:83S-90S https://doi.org/10.1016/S0002-9343(98)00158-2 PMid:9790487
10. Jordan KM, Landis DA, Downey MC, Osterman SL, Thurm AE, Jason LA: Chronic fatigue syndrome in children and adolescents: a review. J Adolesc Health 1998; 22:4-18 https://doi.org/10.1016/S1054-139X(97)00212-7 PMid:9436061
11. Afari N, Buchwald D. Chronic Fatigue Syndrome: A Review. Am J Psychiatry. 2003;160(2):221-236. https://doi.org/10.1176/appi.ajp.160.2.221 PMid:12562565
12. Institute of Medicine (IOM). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press; 2015.
13. Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V: Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 35: 283-289 https://doi.org/10.1016/0165-0327(95)00026-J PMid:8550954
14. Vercoulen JHMM, Swanink CMA, Zitman FG, Vreden SG, Hoofs MP, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G: Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347:858-861 https://doi.org/10.1016/S0140-6736(96)91345-8 PMid:8622391
15. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, Garcia Borreguero D, Blackwelder W, Straus SE: Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998; 280:1061-1066 https://doi.org/10.1001/jama.280.12.1061 PMid:9757853
16. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J: Lowdose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999; 353:455-458 https://doi.org/10.1016/S0140-6736(98)04074-4 PMid:9989716
17. Wilson A, Hickie I, Lloyd A, Wakefield D: The treatment of chronic fatigue syndrome: science and speculation. Am J Med 1994; 96:544-550 https://doi.org/10.1016/0002-9343(94)90095-7 PMid:8017453
18. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J: A doubleblind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990; 89:561-568 https://doi.org/10.1016/0002-9343(90)90173-B PMid:2146875
19. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, Gillespie DH: A controlled clinical trial with a specifically configured RNA drug, poly(I):poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994; 18 (suppl 1):S88-S95 https://doi.org/10.1093/clinids/18.Supplement_1.S88 PMid:8148460
20. Natelson BH, Cheu J, Hill N, Bergen M, Korn L, Denny T, Dahl K: Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 1998; 37:150-154 https://doi.org/10.1159/000026494 PMid:9597672
21. White PD, Cleary KJ: An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. Int Clin Psychopharmacol 1997; 12:47-52 https://doi.org/10.1097/00004850-199701000-00007 PMid:9179634
22. Afari N, Buchwald D. Chronic Fatigue Syndrome: A Review. Am J Psychiatry. 2003;160(2):221-236. https://doi.org/10.1176/appi.ajp.160.2.221 PMid:12562565
23. Institute of Medicine (IOM). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press; 2015. Available from: 1
24. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners. 2012. Available from: 1
25. Saifi MW, Fahad A, Bihari L, Nuzhat, Nilofar S, Fatma KF, Almas U, Shams NF, Jamal Y. An Observational Analytical Study of the Fatigue Index in Young Adult with Reference to Different Mizaj. Int J Adv Health Sci. 2024;11(4):1-9. DOI: 10.5281/zenodo.12743847.
26. Wearden A, Morriss R, Mullis R: A double-blind placebo-controlled trial of fluoxetine and graded exercise for chronic fatigue syndrome (abstract). Eur Psychiatry 1996; 11(suppl 4): 273 https://doi.org/10.1016/0924-9338(96)88824-9
27. Deale A, Chalder T, Marks I, Wessely S: Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997; 154:408-414 https://doi.org/10.1176/ajp.154.3.408 PMid:9054791
28. Deale A, Chalder T, Wessely S: Illness beliefs and treatment outcome in chronic fatigue syndrome. J Psychosom Res 1998; 45: 77-83 https://doi.org/10.1016/S0022-3999(98)00021-X PMid:9720857
Published
Abstract Display: 315 
PDF Downloads: 473 PDF Downloads: 68 How to Cite
Issue
Section
Copyright (c) 2025 Rafat Afzal , Saif Ali Siddiqui
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.